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bstract
The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated.
 multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition
nd management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then
valuated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical
efinition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a review
f recent literature in these topics.
 2015 Elsevier Ireland Ltd. All rights reserved.
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.  Introduction
Chemo-radiotherapy (CRT) has increased the curability of
ocally advanced head and neck cancer patients (HNCPs) [1]
nd has allowed organ and function preservation in laryngeal
nd hypo-pharyngeal cancer patients [2]. However, compet-
ng causes of mortality (e.g. acute and late toxicities) are
ncreased and substantially reduce the overall survival benefit
3,4].
In CRT trials the acute mortality is described in the range
rom 2% [5] to 9.3% [6]. Infection is one of the main causes
f acute mortality [6,7].
Unfortunately, the reporting of infection is sparse even in
andomized trials and the problem is likely underestimated.
(here are three main limitations in interpreting data from
RT trials:
1) Infection-related mortality can be confounded with other
potential causes of death or categorized as “due to an
unknown cause” [6], as the recognition of sepsis requires
an active search and finite criteria. Most importantly
unexplained organ failure (renal, respiratory, cardiovas-
cular, coagulation, multi-organ etc.) is often reported as
the cause of death while the probable relationship with
underlying sepsis syndrome is not recognized.2) Organ damage due to the systemic inflammatory
response is often misinterpreted as being related to the
individual toxicities of the treatment. In a retrospective
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analysis of 394 patients enrolled in consecutive CRT
phase II trials at the University of Chicago, 14 deaths
were attributed to infection and eight cases of pneumonia
were considered “comorbidities” [6]. In total, 22 deaths
(5.6%) were certainly due to infectious complications.
Another 10 deaths were classified as due to “unknown
reasons” or due to factors that could possibly be related
to sepsis (small bowel necrosis, cardiac causes, “other
respiratory disease” etc.). In addition, only recently have
the abscopal effects of local inflammation toxicity been
described [8–10]. Treatments enhancing local toxicity
seem to be related to a higher degree of severe compli-
cations and deaths [11].
3) Finally, the infectious-related mortality is not limited to
the time of CRT administration but can occur several
weeks after treatment [12]. Post-treatment infections and
deaths are usually not considered treatment-related.
We feel that the lack of recognition of the connection
etween the single toxicities and the systemic consequences
s due to insufficient knowledge about infection, sepsis and
ts sequelae. The definitions of these conditions have been
volving over the last 20 years. Consequently, the various
pecialists, such as medical oncologists (MOs), radiation
ncologists (ROs), infectious disease physicians (IDPs) and
ritical care physicians (CCPs) treating HNCPs, use the ter-
inology with different meanings. In fact, while years ago
before 1989) the term sepsis referred solely to a severe bac-
erial infection and was often confused with the infection
tself, more recently sepsis has been defined as a systemic
yndrome [13,14] that encompasses multiple signs and symp-
oms resulting from the body’s reaction to infectious systemic
mmune responses [15,16]. Helpful to the understanding
f sepsis is the definition of the Systemic Inflammatory
esponse Syndrome (SIRS), indicating the unique, highly
reserved systemic response to tissue damage (either infec-
ious or non-infectious) [14,17].
For all these reasons MOs, ROs, CCPs and IDPs from
taly met in Milan from February 17–18, 2013 with the aim of
eaching a consensus on a clinical definition and management
f infections and sepsis in CRT-treated HNCPs.
The results of the literature review and the statements that
btained consensus are reported and discussed in this paper.
.  Material  and  methods
The Delphi appropriateness method was used for this Con-
ensus [18].
The panel, a group of 37 multidisciplinary experts (MOs,
Os, IDPs, CCPs, nutritionists and nurses), met in Milan from
ebruary 17–18, 2013 and appointed a facilitator board of 12
xpert members, from different clinical settings (6 MOs, 4
Os and 1 IDP and 1 CCP). The facilitator board performed a
ystematic review of the literature on infection in CRT-treated
NCPs.
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The MEDLINE database was searched for English-
anguage studies published from 1992 to March 2013
ontaining the terms sepsis, head and neck cancer, noso-
omial, healthcare-acquired, infections, chemotherapy (CT),
nd radiotherapy (RT).
Potentially relevant abstracts presented at annual meet-
ngs of the American Society of Clinical Oncology and of the
uropean Society of Medical Oncology were examined. The
tudy selection included the following: (a) observational and
rospective studies about assessment and treatment; (b) ran-
omized, double-blind, placebo-controlled, or uncontrolled
tudies; (c) retrospective and uncontrolled studies; (d) sys-
ematic reviews and meta-analyses; (e) consensus guidelines.
urthermore, the electronic search results were supplemented
y manual examination of reference lists from selected arti-
les.
On the basis of this literature review, the facilitators iden-
ified a number of key statements.
All the experts rated these statements through a two-round
rocess. A 4-grade scale was used, where 1 was defined
s high consensus, 2 was defined as low consensus, 3 was
efined as no consensus, and 4 was chosen by panelists when
hey felt unable to express an opinion.
A web meeting was held before the second rating, where
tatements were discussed. The statements that received a
eak approval (<75/100) were redefined according to the
bservations of panelists. The second ratings were analyzed
o identify the statement that reached a consensus.
Each expert (including facilitators) was equally weighted
n scoring the statements.
External MOs (JBV, BM), RO (JB), IDP (AC), supportive
ancer care specialist (JR-D), and CCPs (MVR and RPD)
eviewed the statements.
The panelists had a second meeting in Milan on May 5,
014 in order to approve the final version of the statements.
. Results
Consensus-reached statements are listed in Table 1.
. Comments
.1.  General  statements
.1.1.  Epidemiology
The rate of infection during CRT is around 19%, the acute
ortality of CRT is between 2% and 9.3% and the majority
f deaths occurring within 30 days from the end of treatment
s infection-related..1.2.  Definition  of  Sepsis  syndrome
The panel adopted the nomenclature and definitions
or terms used by 2001 International Sepsis Definitions
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Table 1
Consensus-reached statements.
Cluster Phase Descritpion Whom is it in
charge of?
The degree
of consensus
1 Before CRT General statements
.1.1 Epidemiology: The rate of infection during CRT is around 19% [5,151–156], the acute
mortality of CRT is between 2% [5] to 9.3% [6], and the majority of deaths occurring within
30 days from the end of treatment is infection-related
Clinical Oncologist
and nurse
Not rateda
.1.2 Definition of Sepsis syndrome: The panel adopted the nomenclature and definitions for
terms used by 2001 International Sepsis Definitions Conference (i.e. SIRS, sepsis, severe
sepsis, and septic shock) (see Table 2) [23]
Clinical Oncologist
and nurse
82%
.1.3 Etiology and pathogenesis of systemic inflammatory response syndrome (SIRS) and
Sepsis in HNCPs: any kind of tissue damage can induce a SIRS through circulating
mediators. When this response is prolonged and associated with infection it can result in
severe sepsis and its complications [19,44].
Clinical Oncologist
and nurse
Not rateda
.1.4 Predisposing Factors. HNCPs with habits such as smoking [46,47] and alcohol [48]
consumption, malnutrition [82,157], swallowing impairment with aspiration [45],
chemotherapy-induced neutropenia [39,158,159], disruption of physiological barriers as a
consequence of radiodermitis and mucositis [40,160], gingival pockets and dental caries
[161–164], age [12,165,166], co-morbidities such as diabetes and chronic obstructive
pulmonary disease (COPD) [166], and the presence of central venous catheters, gastrostomy
and tracheostomy are at a higher risk of infections.
Clinical Oncologist,
nurse and patient
80%
2 during CRT Statements about Monitoring and Diagnosis of Sepsis.
.2.1. The diagnosis and monitoring of SIRS:
.2.1.1 SIRS should be assessed at least weekly in all HNCPs undergoing CRT through vital
parameter monitoring (blood pressure, heart rate, respiratory rate, and digital oxymetry etc.),
and white blood cell count.
Clinical Oncologist
and nurse
85%
.2.2. The diagnosis of Sepsis
.2.2.1 In the case of SIRS, the search for an associated infection should be rapidly performed
through clinical examination, radiological imaging, blood cultures, and culture from the
suspected sites of infection (urine, sputum, stools, needle aspirate or swabs of skin lesions).
Unfortunately, positive cultures are obtained only in one third of cases and their negativity
does not rule out the presence of infection (mainly due to concomitant antibiotic use,
inadequacy of samples sent to the microbiology laboratory).
Clinical Oncologist
and nurse
95%
.2.2.2 Mandatory cultures of all suspected sites of infection and radiological imaging should
be performed before the start of antibiotic treatment in order to improve the rate of etiologic
diagnosis.
Clinical Oncologist
and nurse
100%
.2.2.3 C-Reactive Protein (CRP) and/or procalcitonin and plasma lactate can add useful
information about infection diagnosis, hence these blood levels may be considerd in case of
suspected infection.
Clinical Oncologist
and nurse
78%
.2.3. The evaluation of organ dysfunction or tissue hypoperfusion
.2.3.1 The evidence for organ dysfunction or tissue hypoperfusion should be accomplished
with urine input/output evaluation, serum lactate, full biochemistry (with renal and liver
function tests, coagulation), and arterial blood gas analysis.
Clinical Oncologist
and nurse
95%
3 during CRT Statements about Hospitalization and antineoplastic treatment interruption
.3.1. Hospitalization: HNCPs with sepsis should be promptly hospitalized as this condition
can progress rapidly
Clinical Oncologist 98%
.3.2. CT interruption: For suspected or confirmed severe sepsis during CRT, CT should be the
first treatment to be interrupted.
Clinical Oncologist 95%
.3.3. RT interruption: For suspected or confirmed sepsis during CRT, RT should be stopped
only in particularly compromised patients or in the presence of severe sepsis.
Clinical Oncologist 78%
4 during CRT Statements about the Early Empirical Antimicrobial treatment
.4.1. Empirical antibiotic therapy should be started within 3 h of clinical presentation [70] Clinical Oncologist
and nurse
100%
.4.2. For suspected or confirmed sepsis (systemic inflammatory response to infection; see
Table 2) empirical antibiotic therapy should be started, considering both anti Gram+ and anti
Gram- antibiotics [108,109]. It should attempt to provide antimicrobial activity against the
most likely pathogens based upon the potential source of infection searched on the basis of
each HNCP’s presenting illness
Clinical Oncologist,
Infectious Disease
Physician and nurse
95%
.4.3. Empirical antibiotic therapy has to be based on local surveillance, antibiotic sensitivity
and infection rate/prevalence; otherwise a rational use of antibiotics in accordance with
international guidelines is advisable (e.g. Centers for Disease Control and Prevention CDC)
Clinical Oncologist,
Infectious Disease
Physician and nurse
80%
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Table 1 (Continued)
Cluster Phase Descritpion Whom is it in
charge of?
The degree
of consensus
.4.4. Considering the very high rate of infection sustained by multi- and pan- resistant
microorganisms in the HNCPs as well as in the general population, when local guidelines are
not available, it is suggested that treatment with broad spectrum, potent antibiotics active
against enterobacteriaceae and methicillin-resistant Staphylococcus aureus be started [108].
Clinical Oncologist
and Infectious
Disease Physician
94%
.4.5. In the presence of sepsis following an oral cavity infection, the treatment might consider
the introduction of an antifungal agent associated with an anti-Gram+ antibiotic
Clinical Oncologist,
Infectious Disease
Physician and nurse
82%
.4.6. Once aspiration pneumonia is suspected, a low threshold for CT scan and diagnostic
bronchoscopy should be maintained.
Clinical Oncologist,
Infectious Disease
Physician and nurse
95%
.4.7. For healthcare-associated infections non-responsive to the first line of antibiotics, the
IDPs’ assessment is mandatory.
Clinical Oncologist,
Infectious Disease
Physician and nurse
100%
5 during CRT Statement about the antibiotic de-escalation procedure:
.5.1. The empirical treatment must be optimized when microbiology results are available. Clinical Oncologist,
Infectious Disease
Physician
100%
6 during CRT Statements about Early Goal-Directed Treatment (EGDT)
: .6.1. In cases of severe sepsis (sepsis + organ failure) supportive therapy using the “EGDT”
scheme should be applied as soon as possible: oxygen administration, hydration with
crystalloids and targeting a Svo2 of 70%.
Clinical Oncologist,
Infectious Desease
Physician.
78%
.6.2. Most patient with severe sepsis (see Table 4) should be rapidly referred to an intensive
care unit (ICU)
Clinical Oncologist,
Infectious Disease
Physician and
Critical Care
Physician
100%
7 After CRT Statement on the Follow up:
.7.1. Monitoring for SIRS parameters should be continued after the end of CRT until the
complete resolution of acute toxicities. Indeed, mortality for pneumonia is reported to occur
well after 30 days from the end of treatments and there is a high risk of infection for several
months
Clinical Oncologist
and nurse
95%
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aa Statements that do not need to be rated.
onference (i.e. SIRS, sepsis, severe sepsis, and septic
hock) (Table 2).
Before 1989 [13,14], “sepsis” was considered to be a sys-
emic infection, often described as “blood poisoning” and
ssumed to be the result of the host’s invasion by pathogenic
rganisms that then spread within the bloodstream. After the
dvent of modern antibiotics, germ theory could not fully
xplain the pathogenesis of sepsis: researchers suggested that
t is the host, not the germ, that drives the pathogenesis of
epsis [19].
Recently a “Consensus conference” attempted to “provide
 conceptual and practical framework to define the sys-
emic inflammatory response to infection” [17]. The acronym
IRS (Systemic Inflammatory Response Syndrome) was
sed in order to provide a reference for the complex find-
ngs that result from a systemic activation of the immune
esponse, triggered by a variety of infectious and noninfec-
ious conditions. Yet, the identification of sepsis through the
992-consensus SIRS criteria had a high sensitivity but a
ow specificity. Indeed, the same criteria can be found in
on-infectious conditions [20] and may represent an appro-
riate physiological reaction [21,22]. In 2001 an International
r
b
(epsis Definitions conference revisited the SIRS criteria (see
able 2) [23] by expanding the list of possible signs of sys-
emic inflammation in response to infection to the physical
nd laboratory findings indicative of early organ dysfunction,
ltered tissue perfusion, and hemodynamic failure, as well.
Thus, even though the 1991 four criteria for sepsis con-
inue to be used because they are easily measurable [24,25],
n presence of suspected sepsis, the other items included in
he 2001-consensus list in order that the presence of some
egree of organ dysfunction, altered tissue perfusion, and/or
emodynamic failure have to be actively searched.
.1.3. Etiology  and  pathogenesis  of  systemic
nflammatory  response  syndrome  (SIRS)  and  Sepsis  in
NCPs
Any kind of tissue damage can induce a SIRS through
irculating mediators. When this response is prolonged and
ssociated with infection it can result in severe sepsis and
elated complications.
Recently the definition of immunity reactions has
een revisited [26,27]: either endogenous danger signals
danger/damage-associated molecular patterns – DAMPs)
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Table 2
Nomenclature and definitions for terms used in critical illness.
Nomenclature Note Clinical disease Clinical signs
Infection A microbial phenomenon
characterized by a local inflammatory
response to the presence of
microrganisms or the invasion of
normally sterile host tissue by those
organisms (or by their products)
Localized
inflammation
Tumor, rubor, calor, dolor and function laesa
Bacteraemia The presence of viable bacteria in the
blood. The presence of viruses,
fungi, parasites should be described
in a similar manner (viremia,
fungemia, parasitemia)
Could be silent Could be silent [167] (6)
SIRS Symptoms and signs related to
panoply of non-specific
inflammatory response.
Systemic
Inflammatory
Response Syndrome:
Bone version 1991
[14] 11
Two or more:
•  Temperature >38 ◦C or core temperature <36 ◦C
• Heart rate > 90 beats/min
• Respiratory rate > 20 breaths/min or PaCO2 < 37 mmHg or
mechanically ventilated
• Leukocyte count > 12,000/l or <4000/l
Sepsisa Systemic inflammatory response to
infection.
Recently, some Authors [168] 28
have defined sepsis when organ
failures are documented
Diagnostic criteria for
sepsis [23] b)
General parameters
– Fever (core temperature >38.3 ◦C)
– Hypothermia (core temperature <36 ◦C
– Heart rate >90 bpm or >2 SD above the normal value for age
– Tachypnea: >30 bpm
– Altered mental status
– Significant edema or positive fluid balance (>20 ml/kg over
24 h)
– Hyperglycemia (plasma glucose >140 mg/dl or 7.7 mM/l) in
the absence of diabetes
Inflammatory parameters
– Leukocytosis (white blood cell count >12,000/l)
– Leukopenia (white blood cell count <4000/l)
– Normal white blood cell count with >10% immature forms
– Plasma C reactive protein >2 SD above the normal value
– Plasma procalcitonin >2 SD above the normal value
Hemodynamic parameters
– Arterial hypotension (systolic blood pressure <90 mmHg,
mean arterial pressure <70 mmHg, or a systolic blood pressure
decrease >40 mmHg in adults or <2 SD below normal for age)
– Mixed venous oxygen saturation >70%
– Cardiac index >3.5 l min
Organ dysfunction parameters
– Arterial hypoxemia (PaO2/FIO2 <300)
– Acute oliguria (urine output <0.5 mL/kg/1 h or 45 mM/l for at
least 2 h)
– Creatinine increase ≥0.5 mg/dl
– Coagulation abnormalities (international normalized ratio
>1.5 or activated partial thromboplastin time >60 s)
– Ileus (absent bowel sounds)
– Thrombocytopenia (platelet count <100,000/l)
– Hyperbilirubinemia (plasma total bilirubin >4 mg/dl or
70 mol/l)
Tissue perfusion parameters
– Hyperlactatemia (>1 mol/l)
– Decreased capillary refill or mottling
Severe Sepsis (Sepsis
with organ
dysfunction)a
Symptoms and signs related to
panoply of nonspecific inflammatory
response and to dysfunctions of
organs and of microvasculature.
Deteriorating
evolution of systemic
inflammation
Sepsis + organ dysfunctions (due to abnormal organ perfusion)
in acutely ill patients
Septic Shocka Sepsis + refractory (unresponsive to fluid and vasopressors)
hypotension+ perfusion abnormality
a Septicaemia was the archaic term to identify these syndromes.
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Fig. 1. Pathogenesis of inflammatory responses: local and systemic effects [20]. Legend: radiochemotherapy on the treated tissues causes damage that facilitates
inflammation. Furthermore germs may more easily spread via the bloodstream after translocation through disrupted barriers: (1) mouth, (2) respiratory tract,
(3) intestinal mucosa, (4) skin and (5) devices. Released cytokines act not only locally but also on other organs and tissues (Inter-organ signaling). On muscles
they can alter energetic metabolism (thus favoring cachexia). On HPA (hypothalamic–pituitary–adrenal axis) they cause fever and fatigue symptoms. On the
liver they provoke the synthesis of acute phase proteins that in turn act in a procoagulative and general inflammatory and anti-inflammatory sense. All these
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sepsis-related multiple organ dysfunction [50]. As onco-ffects can lead to systemic inflammatory response syndrome (SIRS) or sep
ysfunction Syndrome; Other abbreviations see the text.
28,29], generated by stressed host cells, or exogenous
athogen-associated molecular patterns (PAMPs) [30–32]
re recognized as being capable of activating the pattern
ecognition receptors (PRRs) [33] of the immune cells and
s promoting the synthesis of inflammation mediators. Thus,
ny kind of tissue damage (pathogens [34,35], CRT [8,9]
tc.) can induce a local [27,36] and systemic inflamma-
ory response through circulating mediators (Fig. 1) [8,9,20].
ome Authors [37] postulated that anti-inflammatory medi-
tors predominate within the bloodstream to avoid igniting
ew inflammatory foci, while their presence within tissues
ay not always be sufficient to prevent the initiation of a
eleterious inflammatory response in various compartments
38]. Consequently, the sepsis/SIRS-patient plasma behaves
s an immunosuppressive milieu [39]. A consequence of this
eregulation is the fact that germs may more easily spread via
he bloodstream after translocation through disrupted barriers
skin and mucosal barrier injury [40]).
Thus, it has become apparent that when prolonged or
ntensive host responses are provoked (infections, trauma, or
RT) [41–43] both pro-inflammatory and anti-inflammatory
echanisms (involving cytokines) can contribute to infec-ion clearance, organ injury and secondary infections [44]
Fig. 1). During CRT, HNCPs have a number of conditions
redisposing to infection [45], making them extremely at risk.
l
f
e
sbreviations: PaCO2 = arterial carbon dioxide tension; MODS: Multi-organ
.1.4.  Predisposing  factors
HNCPs with habits such as smoking [46,47] and alcohol
48] consumption, malnutrition, swallowing impairment with
spiration, chemotherapy-induced neutropenia, disruption
f physiological barriers as a consequence of radiodermi-
is and mucositis, gingival pockets and dental caries, age,
o-morbidities such as diabetes and chronic obstructive pul-
onary disease (COPD), and the presence of central venous
atheters, gastrostomy and tracheostomy are at a higher risk
f infections.
.2.  Statements  about  monitoring  and  diagnosis  of
epsis
The early identification of sepsis and implementation
f early therapies have been documented to improve
utcomes and decrease sepsis-related mortality [49]. Reduc-
ng the time to diagnosis of severe sepsis is thought
o be a critical component of reducing mortality fromogical patients with sepsis are logically not different
rom other septic patients, the panel recommends an
arly diagnosis of sepsis by following the three main
teps:
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Table 3
Infection probability scorea (IPS) [51].
0 1 2 3 6 8 12
Body temperature (◦C) ≤37.5 ≥37.5
Heart rate (beats/min) ≤80 81–140 >140
Respiratory rate (breaths/min) ≤25 >25
White Blood Cell (×103/mm3) 5–12 >12 <5
C-RP (mg/dL) ≤6 >6
SOFAb score (see Table 4) ≤5 >5
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-a Patients with a score <14 points have only a 10% risk of infection.
b Sequential organ failure assessment.
. Diagnosis and monitoring of SIRS.
. Diagnosis of Sepsis.
. Evaluation for organ dysfunction or tissue hypoperfusion.
.2.1. The  diagnosis  and  monitoring  of  SIRS
.2.1.1.  SIRS  should  be  assessed  at  least  weekly  in  all
NCPs undergoing  CRT  through  vital  parameter  monitor-
ng (blood  pressure,  heart  rate,  respiratory  rate,  and  digital
xymetry etc.),  and  white  blood  cell  count.  SIRS parameters
eed monitoring. Indeed, even if the finding of two positive
IRS parameters is not specific, it may help physicians to
raduate the urgency of intervention, to promptly activate the
earch for infection, and to shorten the time to start antibiotic
dministration. In addition, it is suggested that other diag-
ostic parameters for sepsis, such as those suggested by the
nd consensus conference [23], be performed as a regular
rocedure [22].
Another important role of the assessment of SIRS criteria
an be the evaluation of patients with local tissue damage or
nfection. In CRT-treated HNCPs the occurrence of stomati-
is, in-field skin toxicity, or device-related skin infection can
e either a local limited phenomenon or a systemic evolv-
ng response [20]. The latter deserves a timely application
f systemic treatment. Thus, more frequent analysis (at least
aily) of SIRS criteria has the potential of capturing the sys-
emic evolution of a local inflammation and of orienting all
he following management strategies.
Recently, Peres Bota et al. [51] developed an infection
robability score (IPS) which uses six variables (Table 3) to
ssess the likelihood of infection, resulting in a score from 0 to
6: the 14 score cut-off proved to be reliable enough (positive
redictive value = 53.6%; negative predictive value = 89.5%)
n distinguishing infectious (≥14) from non-infectious (<14)
IRS. In addition, changes in IPS over time may be useful in
ollowing the response to antimicrobial therapy [52].
.2.2. The  diagnosis  of  Sepsis
4.2.2.1 In  the  case  of  SIRS,  the  search  for  an  associated
nfection should  be  rapidly  performed  through  clinical
xamination, radiological  imaging,  blood  cultures,  and
ulture from  the  suspected  sites  of  infection  (urine,  sputum,
tools, needle  aspirate  or  swabs  of  skin  lesions).  Unfortu-
ately, positive  culture  results  are  obtained  only  in  one  third
f cases  and  their  negativity  does  not  rule  out  the  presence if  infection  (mainly  due  to  concomitant  antibiotic  use,
nadequacy of  samples  sent  to  the  microbiology  laboratory)
4.2.2.2 Mandatory  cultures  of  all  suspected  sites  of  infec-
ion and  radiological  imaging  should  be  performed  before  the
tart of  antibiotic  treatment  in  order  to  improve  the  capability
o achieve  etiologic  diagnosis
4.2.2.3 C-Reactive  Protein  (CRP)  and/or  procalcitonin
nd plasma  lactate  can  add  useful  information  about  infec-
ion diagnosis,  hence  these  blood  levels  may  be  considered
n case  of  suspected  infection
The first step in assessing the patient with suspected
epsis is to determine the actual risk of infection and the
ikely source by obtaining information regarding colonizing
r infecting pathogens: the nature of any localizing symptoms
nd signs should be noted. At any rate, the altered immune
unction may not present the typical sign of inflammation and
ay occult the localizing signs. Thus, any suspected source
ust be examined (skin, presence of devices, leg thrombosis,
eck, mucosae and lungs.)
SIRS-positive HNCPs should undergo laboratory, micro-
iological, and radiological evaluation after an infection
robability assessment based on history and physical exam-
nation.
- Laboratory evaluation
 Thrombocytosis, thrombocytopenia, hyperglycemia,
metabolic acidosis, and changes in the inflammatory
status. Even though TNF, IL-1, IL-6, IL-8, and IL-10 are
all important in sepsis, they are not specific for inflamma-
tion/organ dysfunction, and do not assist in distinguishing
between infectious and non-infectious causes.
 C-Reactive Protein (C-RP) and/or procalcitonin, although
not always associated with infection [53–58], can add use-
ful information about its diagnosis.
 C-RP levels > 17 mg/dl have been suggested as providing
a means of separating patients with sepsis from those with
non-septic inflammatory response due to other causes (e.g.
trauma)[59].
 Procalcitonin has been proposed as a marker of infection
[60–63]. Furthermore, it may be useful as an indicator of
the severity of infection and as a guide for therapy (dose
de-escalation [64]) in respiratory infections [61,62,65–68].
Thus, these markers cannot be recommended distinguish-
ng between severe infection and other acute inflammatory
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tates [69], but they can be helpful adjunctive diagnostic
arkers to be interpreted in context with information from
areful medical history, physical examination.
- Microbiological evaluation:
Obtaining cultures before antimicrobial administration is
ssential to confirm infection, to appropriately target antibi-
tic therapy and to allow antimicrobial de-escalation after
eceipt of the susceptibility profile [70]. Unfortunately, posi-
ive results are obtained only in one third of the cases and
heir negativity does not rule out the presence of infec-
ion [71]. Considering that the first antimicrobial dose can
apidly sterilize blood cultures within a few hours, obtaining
hose cultures before therapy is essential. Thus, at least two
lood cultures, both peripherally and via indwelling catheters
re recommended [70,72–74]. Although some guidelines
70] recommend that cultures should not cause significant
elay (>45 min) in starting antimicrobial administration,
ome authors suggest that non-neutropenic and stable patients
hould be observed without empirical antibiotics while con-
idering further diagnostic evaluation [75].
If fungal infection is suspected, 1-3b-d-glucan, mannan
nd anti-mannan antibody assays have shown positive results
ignificantly earlier than with standard culture methods [70].
alse positive reactions can occur with colonization alone
76].
Microbiological samples should also be taken from sites
hat are suspected of being infected.
- Radiological evaluation:
In order to identify the infection sources, imaging may
elp. Ultrasonography, performed at the bedside, can assist
n localizing a fluid collection and may allow for per-
utaneous drainage and microbial cultures. CT scanning
an help identify thoracic, abdominal, and deep-space
nfections. White Indium111-labeled blood-cell scans and
ndium111 Immunoglobulin-G have poor sensitivity and
pecificity, whereas Technetium scans seems to be more
seful, owing to its high specificity (93–94%), but it has a
oor sensitivity (40–75%) [77]. Finally, Fluorodeoxyglucose
ositron-emission tomography (FDG-PET) scans have a high
ensitivity (95%) and a good specificity (88%) in identify-
ng septic sources in patients with fever of unknown origin
77–79].
.2.3.  The  evaluation  of  organ  dysfunction  or  tissue
ypoperfusion
.2.3.1. The  evidence  for  organ  dysfunction  or  tissue  hypop-
rfusion should  be  accomplished  with  urine  input/output
valuation, serum  lactate,  full  biochemistry  (with  renal  and
iver function  tests,  coagulation),  and  arterial  blood  gas  anal-
sis. Sepsis and non-infectious SIRS can induce the MODS.
he number of organ failures during sepsis increases the
isk of mortality [80–82]. Thus, assessment of bone marrow,
enal, liver, brain, coagulation, respiratory and circulatory
unctions through laboratory examinations and clinical mon-
toring should always be associated with the search for the
nfection site (Table 4).
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The term “severe sepsis” was proposed to describe
nstances in which sepsis is complicated by inadequate
issue perfusion or organ dysfunction [83]. Capillary bed
ypo-perfusion causes dysoxia, due to both altered micro-
irculation (“supply-dependent  dysoxia”)  [83,84] and the
nhibition of mitochondrial respiratory enzymes caused
y toxic oxygen and nitrogen intermediates (“cytopathic
ypoxia”) [85,86].
Other causes of peripheral hypoxia are the myocardial
ontractility depression, owing to a variety of myocardial
epressants found in the septic-patient plasma (such as TNF-
, IL-1, IL-6 and nitric oxide) [87,88], and the acute lung
njury due to damage to the pulmonary vascular circulation
nd the alveolar-capillary membranes.
As a consequence of the above-mentioned causes,
he circulatory abnormalities (intravascular volume deple-
ion, peripheral vasodilatation, myocardial depression) and
ncreased metabolism lead to an imbalance between sys-
emic oxygen delivery/demand, resulting in global tissue
ypoxia or even shock. As the cardiovascular system is
esigned to preserve arterial blood pressure to maintain
erebral and coronary perfusion during stress by reducing
erfusion to peripheral tissues, the routine vital signs, central
enous pressure and urinary output [89,90] may be rela-
ively insensitive measures of early circulatory shock (also
nown as “cryptic shock” [90]), whereas serum lactate lev-
ls can serve as a marker of occult hypoperfusion [91,92].
ndeed, patients with cryptic hypoperfusion are often over-
ooked as candidates for aggressive interventions because
hey are hemodynamically stable [93], but they are associated
ith increased mortality [92,94–97]. Thus, the main endpoint
n sepsis treatment is to recognize the imbalance between
xygen delivery/demand measuring serum lactate in order to
tart resuscitation promptly [70,93] (the so called Early Goal
irected therapy (EGDT)). Current critical care guidelines
ecommend measuring serum lactate in hemodynamically-
table patients with sepsis to assess for occult hypoperfusion,
ince an elevated lactate level (≥4 mmol/L) may warrant ICU
ransfer. Recent evidence (non-randomized trials) suggests
hat the serum lactate threshold used to identify patients eli-
ible for EGDT be lowered, given the association between
odestly elevated serum lactate levels (≥2 mmol/L) and
orbidity and mortality [70,96,97]. This transition point
lactate≥2/4 mmol/L) occurs during the critical “golden
ours” when treatment can provide maximum benefits in
erms of outcome [93]. Thus, EGDT policy aims to restore
his balance promptly by manipulating cardiac contractility,
xygenation, and tissue perfusion.
The parameters that monitor this balance between oxy-
en delivery/demand include mixed oxygen saturation
pulmonary-artery oxyhemoglobin saturation representing
otal balance of oxygen consumption and delivery assuming
bility of cells to take up oxygen) (SvO2) or central venous
aturation (ScvO2) (superior half-body oxygen saturation),
actate production, base deficit and pH [98]. Yet, one of the
roblems in the applicability of these guidelines is the need
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Table 4
The goal of supportive treatment: restoration and maintenance of adequate tissue perfusion so as to prevent multiple organ dysfunctions.
Goal Clinical manifestation Monitoring Action Warning
Hemodinamic support (Early Goal Directed therapy)
Tissue
Oxygenation/perfusion:
Early recognition of the imbalance
between oxygen delivery and oxygen
demand measuring serum lactate and
oxygen saturation
lactate level > 2 mmol/L.
maintain O2 sat > 90% or PaO2 > 60 mmHg
Monitor volume overload (VoL)a.
Fluid resuscitation: Administer 30 ml/kg
(0.9% sodium chloride or lactated
Ringer) crystalloid for hypotension or
lactate ≥2/4 mmol/L
After >4 L, if there is
no improvementb or if
there is evidence of
volume overload in
ICU for vasopressor
therapy
Monitor and support MODS SOFA scale [169]
Respiratory [170] No Dysfunction PaO2/FiO2> 400 mm Hg 0
PaO2/FiO2 < 400 mm Hg 1
ALI or mild ARDS PaO2/FiO2 < 300 mm Hg 2 CPAP >5 cm H2O non invasively [171] If non-improving
ICU*
Moderate ARDS PaO2/FiO2< 200 mm Hg 3 PEEP (invasively)* ICU*
Severe ARDS PaO2/FiO2< 100 mm Hg 4
Cardio vascular No hypotension MAP ≥ 70 mmHg 0 Administer fluids (at least 20 ml/Kg
crystalloids in 30 min) and monitor
cardio-vascular and renal dysfunction.*
After >4 L, if there’re
is not improvingb or if
there is evidence of
volume overload in
ICU for vasopressor
therapy
Hypotension MAP < 70 mmHg 1
Dobutamine any dose or Dopamine ≤ 5 g/kg/min 2
Dopamine > 5 g/kg/min or epinephrine or
norepinephrine ≤0.1 g/kg/min
3
Dopamine > 15 g/kg/min or epinephrine or
norepinephrine >0.1 g/kg/min
4
Renal dysfunction Decreased UOP Creatinine <1.2 mg/dl 0
Creatinine <2 mg/dl 1
Creatinine <3.5 mg/dl 2
Creatinine <5 mg/dl
UOP< 500 ml/die
3
Creatinine <1.2 mg/dl
UOP< 200 ml/day
4
Coagulopathy DIC and Bleeding Platelet > 150.000/l 0 Platelet transfusion in pts with DIC and
bleeding (or a high risk of bleeding) with
platelet <50/ml [172] or <20/ml [70]
For the diagnosis and
management of DIC
see the guideline of
BSCH [172]
Platelet < 150.000/l 1
Platelet < 100.000/l 2
Platelet < 50.000/l 3
Platelet < 20.000/l 4
Central nervous system GCS testing:
Eye, Verbal and motor responses
GCS ≥ 15 0
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GCS < 15 1
GCS ≤ 12 2
GCS ≤ 9 3
GCS < 6 4
Hepatic Hepatic failure Bilirubin <1.2 mg/dl 0
Bilirubin <2 mg/dl 1
Bilirubin <6 mg/dl 2
Bilirubin <12 mg/dl 3
Bilirubin ≥1.2 mg/dl 4
General Supportive care
Correction of anemia Haematocrit < 30%
Hemoglobin <7 g/dL
If Hb levels fall <7 g/dL red blood cell is
recommended to a target Hb range of
7–9 g/dL [70]
Depressed Myocardial
performance
Inadequate cardiac index CVP > 8–12 mmHg
MAP < 65
UOP > 0.5 ml/kg/h
ScvO2 > 70% or SvO2 > 65%
Restore haematocrit if <30% then use
inotropic agent (dobutamine up to
20 g/kg/min) [70]*
Metabolism: Maintain blood glucose levels < 150–180 mg/dL
[70,173–177];
Nutritional Weight loss Patient that receive less than 60% of their energy target
from Enteral nutrition
Individually optimized energy
supplementation with parenteral
nutrition [178]
Splanchnic hypoperfusion Stress ulceration, ileus or malabsorption For patients with sepsis stress ulcer prophylaxis with the
use of histamine H2–receptor antagonists may decrease
the risk of gastrointestinal hemorrhage. Proton-pump
inhibitors may be effective but have not been fully
evaluated for stress ulcer prophylaxis
Deep venous thrombosis
(DVT) [70]
Because sepsis increases the risk of deep venous
thrombosis, prophylactic heparin is recommended for
patients who do not have active bleeding or
coagulopathy.
Use mechanical DVT prevention devices
-low-dose unfractionated heparin (UFH;
2 or 3 times daily) or
low-molecular-weight heparin (LMWH);
dalteparin may be used in the case of
patients with creatinine
clearance < 30 mL/min
Acronyms: MODS: Multiorgan dysfunction; SOFA: Sequential Organ Failure Assessment; ALI: acute lung injury; ARDS acute respiratory distress syndrome; CPAP: Continuous Positive Airway Pressure; PEEP:
Positive End Expiratory Pressure; MAP: Mean Arterial Pressure; UOP: Urine Output; DIC disseminated intravascular coagulation; BSCH: British Committee for Standards in Hematology; GCS: Glasgow Coma
Scale; SCvO2: Central Venous Oxygen Saturation; SvO2: Mixed Venous Oxygen Saturation.
* Values or Treatment that, if not effective, indicate patient referal to the ICU.
a
“VoL” clinical signs: dyspnea, elevated jugular pressure, crackles on auscultation, and pulmonary edema on chest Rx;
b improvement after fluid resuscitation of mental status, heart rate, MAP, capillary refill and UOP.
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or invasive procedures such as central venous cannulation,
ecessary for the measurement of central venous pressure
nd SvO2/ScvO2 [99–102]. Recent reports suggest that early
actate [50,103,104] measurements might be equivalent to
vO2/ScvO2 monitoring in order to guide fluid resuscitation.
urthermore, lactate normalization has been shown to be non-
nferior to early resuscitation based on ScvO2 normalization
50,105]. Table 4 lists the parameters that need checking in
rder for organ dysfunctions to be monitored.
.3.  Statements  about  hospitalization  and  antineoplastic
reatment interruption
.3.1.1.  Hospitalization
HNCPs with sepsis should be promptly hospitalized as
his condition can progress rapidly.
.3.1.2. CT  interruption
For suspected or confirmed severe sepsis during CRT, CT
hould be the first treatment to be interrupted.
.3.1.3.  RT  interruption
For suspected or confirmed sepsis during CRT, RT should
e stopped only in particularly compromised patients or in
he presence of severe sepsis.
Sepsis management requires multidisciplinary (oncolo-
ist/hematologist, IDP, CCP, nurses, pneumonologists, and
ieticians), diagnostic and management actions that need
o interact rapidly in order to maximize the chances
f success [70]. Thus, the panel suggests that HNCPs
ndergoing CRT should be hospitalized when diagnostic
riteria for sepsis [23] are associated with a suspected
nfection. This is so that HNCPs can progress more
apidly and that the specific antineoplastic treatments can
ontinue safely by limiting interruption as much as possi-
le.
In addition, the presence of sepsis should induce the inter-
uption of CT administration, given its potential in worsening
rgan damage and in hindering immune responses. CT should
e resumed when every organ failure is resolved and no
ign of SIRS is present. Conversely, the radiotherapeutical
ystemic effects are less dangerous than chemotherapeuti-
al ones: consequently, the panel suggests continuing RT
s the advantage due to local-toxicity recovering could
e annulled by the negative effects of tumor re-growth
106,107]. Of course, the symptoms of local toxicity must
e monitored/controlled.
.4.  Statements  about  the  Early  empirical  antimicrobial
reatment
4.4.1 Empirical  antibiotic  therapy  should  be  started  within
 h of  clinical  presentation
4.4.2 For  suspected  or  confirmed  sepsis  (Systemic  inflam-
atory response  to  infection;  see  Table 2)  empirical
ntibiotic therapy  should  be  started,  considering  both  anti
a
p
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ram+  and  anti  Gram-  antibiotics  [108,109].  It  should
ttempt to  provide  antimicrobial  activity  against  the  most
ikely pathogens  based  upon  the  potential  source  of  infection
earched  on  the  basis  of  each  HNCP’s  presenting  illness
4.4.3 Empirical  antibiotic  therapy  has  to  be  based
n local  surveillance,  antibiotic  sensitivity  and  infection
ate/prevalence; otherwise  a  rational  use  of  antibiotics  in
ccordance  with  international  guidelines  is  advisable  (e.g.
enters for  Disease  Control  and  Prevention  CDC)
4.4.4 Considering  the  very  high  rate  of  infection  sustained
y multi-  and  pan-  resistant  microorganisms  in  the  HNCPs  as
ell as  in  the  general  population,  when  local  guidelines  are
ot available,  it  is suggested  that  treatment  with  broad  spec-
rum, potent  antibiotics  active  against  enterobacteriaceae
nd methicillin-resistant  Staphylococcus  aureus  be  started
4.4.5 In  the  presence  of  sepsis  following  an  oral  cavity
nfection, the  introduction  of  an  antifungal  agent  associated
ith an  anti-Gram+  antibiotic
4.4.6 Once  aspiration  pneumonia  is  suspected,  a  low
hreshold for  CT  scan  and  diagnostic  bronchoscopy  should
e maintained
4.4.7 For  healthcare-associated  infections  non-responsive
o the  first  line  of  antibiotics,  the  IDPs’  assessment  is  manda-
ory
Initiation of therapy may be necessary for unstable or
igh-risk patients while the diagnostic evaluation is ongo-
ng [75]. If an infectious cause of fever is suspected,
mpirical antimicrobial therapy is urgent. Indeed, delay-
ng effective antimicrobial therapy has been associated with
ncreased mortality [49,110–114]. Barie and associates [115]
emonstrated in a prospective observational study that the
elayed-antibiotic therapy increased the risk of death by 2.1%
or every 30 minutes’ delay (OR, 1.021; 95% CI, 1.003 to
.038). Moreover, MacArthur et al. in a randomized trial
btained a 10% decrease in the overall crude-mortality with
n adequate and early empirical antibiotic treatment [116].
hus, antibiotics should be given before obtaining the results
f cultures in any case suspected of having an infection and
hen one or more organ failures are manifested without other
igns of infection.
The initial selection of antimicrobial therapy
hould be broad enough to cover all likely pathogens
110–112,115,117,118]. Kollef et al. showed [117] that the
rior administration of antibiotics (implying an increased
isk of resistant pathogens) and the presence of a bloodstream
nfection (especially catheter-related: implying resistant
ram positive cocci and failure to treat fungemia empirically)
ere the main causes of inappropriate therapy and increased
ortality.
Initial empirical anti-infective therapy includes one or
ore drugs that have activity against all likely pathogens
considering both Gram+ and Gram- and/or fungal or viral)
nd that penetrate in adequate concentrations into the tissues
resumed to be the source of sepsis [70] (Table 5).
Thus, the main aims that should guide the choice of anti-
nfective treatments are [69,70]:
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Table 5
Proposals from the literature of empiric antibiotic antimicrobial choice based on suspected site of infection.
Presume Site of the
source of infection
Local infection or critical colonization Sepsisa,b
Pneumoniac Early onset, low risk for multi-drug resistant
organisms:
Out-patient: ceftriaxone plus azithromycin
500 mg qd or levofloxacin 500 mg bid or
moxifloxacin po 400 mg qd
In-patient (IV) ampicillin/sulbactam 3 g
q8 h, (IV) ceftriaxone plus (IV) azithromycin
500 mg qd or levofloxacin 750 mg qd or
moxifloxacin400 mg qd(IV)
Late onset and/or risk factors for MDR organisms:
Meropenem (IV) 1 g q8 h or
Piperacillin/tazobactam (IV) 4.5 g q6 h or
Imipenem/cilastatin (IV) 500 mg q6 h (1 g q6-8 h if P. aeruginosa is
suspected)
PLUS
Vancomycin (IV) 15–20 mg/kg/dose q8–12 h, or
Linezolid 600 mg (IV) q12 h
Oral cavity Topical forms of fluconazole, Itraconazole,
nystatin suspension intra-orally [179].
Ampicillin/sulbactam 3 g q8 h, (IV)
PLUS
If suspected mycosis:
Fluconazole 100 mg q12 h or Itraconazole oral solution 100 mg
q12h [180]
or
Echinocandins (anidulafungin, caspofungin and micafugnin) or
liposomal amphotericin B only in very severe and refractory cases
[181]
Central venous device
[138]
Early catheter removal (if possible)
Daptomycin 6 mg/kg/dose IV once daily (in absence of pneumonia), or
Vancomycin (IV) 15–20 mg/kg/dose (actual body weight) every 8–12 h
PLUS
Piperacillin/tazobactam (IV) 4.5 g every 6 h or meropenem (IV) 1 g q8 h or imipenem/cilastatin (IV) 500 mg q6 h
(1 g q6-8 h if P. aeruginosa is suspected)
Gastrostomy/Tracheostomy Mupirocin 2%, gentamycin, eritrocyn or
clortetracyclin topical ointment q8 h [182]
Piperacillin/tazobactam (IV) 4.5 g every 6 h or carbapenem
(meropenem (IV) 1 g q8 h or imipenem/cilastatin (IV) 500 mg q6 h
PLUS
Vancomycin (IV) 15–20 mg/kg/dose (actual body weight) every
8–12 h, or
Linezolid 600 mg (IV) q12 h or
Daptomycin (IV) 4 mg/kg/dose once daily, or
Telavancin (IV)10 mg/kg/dose IV once daily.
PLUS
If suspected invasive candidiasis/candidaemia: Caspofungin of
micafungin or liposomal amphotericin B or anidulafungin [181]
Gastrointestinal
Oesophageal
Moxifloxacin 400 mg intravenously (IV) qd
followed by moxifloxacin 400 mg orally
(PO) qd [183,184]
or
Amoxicillin/clavulanate and ciprofloxacin
plus metronidazole [185]
In case of peritonitis:
Piperacillin/tazobactam (IV) 4,5 g q6 h or
Imipenem/cilastatin (IV) 2 g q8 h or
Meropenem (IV) 2 g q8 h 3 or
Tigecycline [185]
PLUS
Echinocandins (anidulafungin, caspofungin and micafugnin) or
liposomal amphotericin B only in very severe and refractory cases
[181]
Diarrhea (consider C.
difficile infection)
Oral Vancomicin 125 mg q6 h for 10 days or
Teicoplanin 200 mg o12 h or
Fidaxomicin 200 mg q12 h for 10 days
Oral Vancomicin 125–500 mg q6 h for 10 days or
Teicoplanin 200 mg o12 h or
Fidaxomicin 200 mg q12 h for 10 days
When oral treatment is not possible, parenteral metronidazole
500 mg tid for 10 days combined with intracolonic or nasogastric
administration of vancomycin.
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Table 5 (Continued)
Presume Site of the
source of infection
Local infection or critical colonization Sepsisa,b
Sepsis [109,186] without
an individuated site
In the case of non-HAI-suspected infection
ampicillin/sulbactam 3 g q8 h, plus
levofloxacin 500 mg qd
In patients with HAI
Daptomycin (IV) 6 mg/kg/dose once daily in absence of
pneumonia, or
Teicoplanin (IV) 12 mg/kg/die or
Vancomycind (IV) 15–20 mg/kg/dose (actual body weight) every
8–12 h or
Linezolid (IV) 600 mg q12 h in absence of bacteremia, PLUS
Piperacillin/tazobactam (IV) 4.5 g every 6 h or
Carbapeneme
PLUS
If suspected mycosis:
Echinocandins (anidulafungin, caspofungin and micafugnin) or
liposomal amphotericin B [181]
a If the patient is “antibiotic experienced” an amynoglicoside rather than a quinolone or cephalosporin for gram- is advisable. In fact certain microorganisms,
chiefly Enterobacteriaceae (e.g., E. coli and K. pneumoniae), contain a beta-lactamase enzyme that inactivates penicillins and cephalosporins (Extended
Spectrum Beta-Lactamase producing bacteria (ESBL) Patients presenting with ESBL-associated risk factors (intra-abdominal), tigecycline is recommended
[185].
b The combined antibiotic therapy should consider pathogens with antibiotic resistance (such as MRSA, Pseudomonas species, and gram-negative organisms
with ESBL activity) increasing the likelihood that at least one drug may be effective against that strain [187,188].
c Typically require dual broad-spectrum antibiotics with overlapping coverage [189–192].
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•In patients with a history of IV drug use, those with indwelling vascular ca
in absence of pneumonia) or vancomycin (IF mic ≤1) or linezolid (in abse
e Cephamycins (e.g., cefotetan) and carbapenems (e.g., imipenem, merop
 The evaluation of risks for infection by multidrug-resistant
pathogens.
HNCPs having been treated with CT during the pre-
ious 30 days should be considered immunocompromised
119–121] and at high risk of healthcare-associated infec-
ions.
 The evaluation of the suspected infection source
The main infection sources in HNCPs are the respiratory
ract, the oral cavity, and medical devices such as central
enous catheters (CVCs) [122], especially total implanted
ccess ports [123], gastrostomy [124], and tracheostomy [47].
 Respiratory infection is the most frequent non-cancer
cause of morbidity/death in HNCPs. Indeed, Soares [82]
and Downey [125] reported that the main reasons for ICU
admission for HNCPs were sepsis and acute respiratory
failure. Other authors [126,127] showed that the most com-
mon causes of non-cancer-associated morbidities/death
are respiratory diseases. Indeed, aspiration of colonized
oropharyngeal contents into the lower respiratory tract can
be due to HNCPs’ swallowing dysfunction [45,128]. Thus,
pneumonia in HNCPs should be considered and treated
according to the health-care acquired pneumonia (HCAP)
criteria due to the frequent involvement of multidrug resis-
tance organisms [121].
 Regarding the oral cavity, a systematic review shows that
clinical oral fungal infection/colonization rises respec-
tively to 37.4%/72% during RT and 38%/74.5% during
CT. Candida albicans (46.2%) was the prevalent colo-
nizing fungi followed by C. tropicalis (16.6%) [129].
Furthermore, shifts in oral bacterial flora (mainly fromor devices, or those with recent hospitalizations an agent such as daptomycin
acteremia) should be adopted.
nd ertapenem) [193] remain effective against ESBL-producing organisms.
streptococci toward coagulase-positive staphylococci)
[130]) have been attributed to CT, xerostomia, antibiotic
use and associated neutropenia [130–132].
 Regarding device-related infection, it must be considered
that a colonized foreign body serves as a continuing source
of infection by multiple mechanisms: it impairs local host
defenses and many of the organisms have the capacity
to form a biofilm on invasive devices and so create a
continuing focus of infection. Coagulase-negative Staphy-
lococci species, for example, create a biofilm and therefore
are a common cause of vascular catheter-related infec-
tions [133]. The infection due to these external-internal
devices may be localized to entrance-site and/or tunnel
(or port-pocket in the case of port-a-cath CVC) and,
when associated to SIRS, is the cause of device-associated
“blood systemic infection” (BSI).
Cancer patients with implantable port systems experi-
enced a median of 0.2 infections per 1000 catheter-days
(range: 0–2.7 per 1000 catheter-days) [134] versus a
risk that ranges from 1.4 to 2.2 infections per 1000
catheter-days for subcutaneous tunneled CVCs [135,136].
Nevertheless, this difference may be biased by the fact
that patients who receive implantable subcutaneous ports
usually receive much less intensive cancer therapy [137].
Thus, the optimal device to be used during CRT is hardly
advisable and needs further prospective trials.
Recommendations for culturing and treatment of
catheter-related BSI are addressed by the Infectious Dis-
eases Society of America [138,139]. In addition, ASCO
guidelines [137] recommend immediate catheter removal
for BSIs caused by fungi and non-tuburculous mycobac-
teria (e.g., M.  chelonei, M.  fortuitum, M.  mucogenicum,
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M.  abscessus). Furthermore, BSIs caused by Bacillus
species, C.  jeikeium, S.  aureus, P.  aeruginosa, S.  mal-
tophilia, and vancomycin-resistant enterococci may be
difficult to eradicate with antimicrobial therapy alone,
and early catheter removal should be considered. Finally,
catheter removal should also be considered when blood
cultures remain positive 48 h after the start of antibiotic
treatment if no other infection site has been identified or if
bacteremia recurs shortly after the completion of a course
of antibiotics.
 Regarding  the  enteral  nutrition, there were significantly
more infections in the PEG group (66%) compared to the
NGT group (30%) p  = 0.001 in the prospective study of
Corry et al. [124], but the difference of pneumonia between
the two groups (PEG = 31.3% vs. NGT = 30%) was statis-
tically insignificant. In fact, the majority of infections in
the PEG group were at the PEG site (31%: 10/32).
 Evaluation of antimicrobial sensitivity of local germ pop-
ulations.
The prevalence of microorganisms differs according to
he environments. Some authors [140] have observed that
ram-positive bacteria prevail over the gram-negative ones as
nfectious pathogen in developed countries, probably because
f the routine use of prophylactic oral antibiotics (such as
uinolones, which can also favor bacteriaceae) [141] and
he use of CVC [140]. Conversely gram-negative prevails
n developing countries [142].
Consequently, most scientific guidelines [70,120] recom-
end recognizing the variability of bacteriology from one
ospital to another over time in order to select the most
ppropriate antibiotic regimen.
.5.  Statement  about  the  antibiotic  de-escalation
rocedure
.5.1.  The  empirical  treatment  must  be  optimized  when
icrobiology results  are  available
The empirical combination antimicrobial therapy should
ot be administered for longer than 3–5 days [70]. After
hat period, treatment de-escalation to the most appro-
riate single-agent therapy should be performed as soon
s the susceptibility profile is known [109]. This should
inimize the risk of inducing toxicity and bacterial resis-
ance, and of developing superinfections with other resistant
rganisms such as Candida species, Clostridium difficile or
ancomycin-resistant Enterococcus faecium. Concern about
nder treatment due to de-escalation is unfounded [143].
he “Surviving sepsis campaign” [70] suggests the dura-
ion of therapy be 7–10 days if clinically indicated; longer
ourses may be appropriate in patients who have a slow clin-
cal response, undrainable foci of infection, bacteremia withRSA; some fungal and viral infections, or immunological
eficiencies, including neutropenia.
The use of procalcitonin [64,144,145] or similar biomark-
rs may facilitate discontinuance of antibiotics in a patient
c
togy/Hematology 95 (2015) 191–213 205
ith clinical improvement, although one recent study failed
o show any benefit of daily procalcitonin measurement [146].
.6.  Statements  about  early  goal-directed  treatment
EGDT)
4.6.1 In  cases  of  severe  sepsis  (sepsis  ±  organ  failure)  sup-
ortive therapy  using  the  “EGDT”  scheme  should  be  applied
s soon  as  possible:  oxygen  administration,  hydration  with
rystalloids,  and  targeting  a  Svo2  of  70%
4.6.2 Most  patients  with  severe  sepsis  (see  Table  4) should
e rapidly  referred  to  an  intensive  care  unit  (ICU)
In 2004, the “Surviving Sepsis Campaign” guidelines
ecommended the use of EGDT [147] based on one large
andomized trial [93]. These guidelines were updated in 2008
148], successively in 2012 [70], and were further supported
y several subsequent trials that corroborated the benefit of
GDT in severe sepsis and septic shock [149].
Rivers [93] showed there was an increase in survival at
8 days through EGDT application in a randomized study in
hich patients with severe sepsis and septic shock received
GDT during the first 6 h after enrolment or the usual ther-
py. EGDT involves identifitcation of high-risk patients (see
able 4), invasive monitoring, and 6 hours of protocolled
esuscitation with fluids, vasoactive agents, and packed red
lood cells. Although these strategies are common in the ICU,
hey are not in oncology or internal medicine wards. Recently,
ome authors have not found any significant benefit of the
andated use of central venous catheterization and central
emodynamic monitoring in all patients [102].
The mechanisms of the benefit of EGDT are unknown
ut may include reversal of tissue hypoxia and a decrease in
nflammation and coagulation defects.
.7.  Statement  about  the  follow  up
.7.1.  Monitoring  for  SIRS  parameters  should  be
ontinued after  the  end  of  CRT  until  the  complete
esolution  of  acute  toxicities.  Indeed,  mortality  for
neumonia is reported  to  occur  well  after  30 days  from
he end  of  treatments  and  there  is  a  high  risk  of  infection
or several  months
Mortality for pneumonia is reported to occur well beyond
0 days after the end of treatments and a high risk of infection
s maintained for several months [6,12]. Indeed, it must be
onsidered that the local damage and nutritional impairment
ast several months after the end of treatment [150], conse-
uently the risk of infection remains higher well after the end
f treatment.
. ConclusionsThe sepsis in CRT-treated HNCPs is a serious much-feared
omplication and constitutes a reason for treatment reduc-
ion, delay, or interruption. It may affect the prognosis and
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ause the death of potentially curable patients. In order to bet-
er manage this adverse event, it is necessary to standardize
linical definitions, diagnosis, management, and treatment
ccording to international guidelines. Since very little has
een written concerning severe sepsis in HNCPs, our review
imed to obtain some indications for the management of
eptic patients from literature and tried to draw up recom-
endations/suggestions for HNCPs, based on the consensus
mong multidisciplinary health professionals. The main aim
s to standardize their diagnostic and treatment behavior.
Obviously, the main limit of this study is the fact that most
iterature is obtained from non-HNCPs.
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